Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Scully

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Vaccine|November 29, 2021
A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccinationKevin Cannon, Charles Elder, Mariano Young, et al.
Vaccine|July 28, 2021
A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of ageNicola P Klein, Paula Peyrani, Kari Yacisin, et al.
Hepatology (Baltimore, Md.)|November 1, 1995
Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysisM Wilschanski, P Chait, J A Wade, et al.
The Pediatric Infectious Disease Journal|May 12, 2015
Group A Streptococcal Carriage and Seroepidemiology in Children up to 10 Years of Age in AustraliaHelen S Marshall, Peter Richmond, Michael Nissen, et al.
Human Vaccines & Immunotherapeutics|March 4, 2021
A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of ageBrandon Essink, James Peterson, Kari Yacisin, et al.
The Pediatric Infectious Disease Journal|March 19, 2024
A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of AgeJay Meyer, Peter Silas, G Laïssa Ouedraogo, et al.
Msphere|August 24, 2018
Two Vaccines for <i>Staphylococcus aureus</i> Induce a B-Cell-Mediated Immune ResponseChristopher D Dupont, Ingrid L Scully, Ross M Zimnisky, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 1, 1995
Kinetics and disposition of picumeterol in animalsA Barrow, S J Camp, S Dayal, et al.
The British Journal of Surgery|January 26, 2017
Vaccine development to prevent Staphylococcus aureus surgical-site infectionsN Mohamed, M Y Wang, J-C Le Huec, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 28, 2020
Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of AgeDonald Hurley, Carl Griffin, Mariano Young, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Vaccine|November 29, 2021
A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccinationKevin Cannon, Charles Elder, Mariano Young, et al.
Vaccine|July 28, 2021
A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of ageNicola P Klein, Paula Peyrani, Kari Yacisin, et al.
Hepatology (Baltimore, Md.)|November 1, 1995
Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysisM Wilschanski, P Chait, J A Wade, et al.
The Pediatric Infectious Disease Journal|May 12, 2015
Group A Streptococcal Carriage and Seroepidemiology in Children up to 10 Years of Age in AustraliaHelen S Marshall, Peter Richmond, Michael Nissen, et al.
Human Vaccines & Immunotherapeutics|March 4, 2021
A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of ageBrandon Essink, James Peterson, Kari Yacisin, et al.
The Pediatric Infectious Disease Journal|March 19, 2024
A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of AgeJay Meyer, Peter Silas, G Laïssa Ouedraogo, et al.
Msphere|August 24, 2018
Two Vaccines for <i>Staphylococcus aureus</i> Induce a B-Cell-Mediated Immune ResponseChristopher D Dupont, Ingrid L Scully, Ross M Zimnisky, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 1, 1995
Kinetics and disposition of picumeterol in animalsA Barrow, S J Camp, S Dayal, et al.
The British Journal of Surgery|January 26, 2017
Vaccine development to prevent Staphylococcus aureus surgical-site infectionsN Mohamed, M Y Wang, J-C Le Huec, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 28, 2020
Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of AgeDonald Hurley, Carl Griffin, Mariano Young, et al.
Pageof 10